An osteosarcoma zebrafish model implicates Mmp-19 and Ets-1 as well as reduced host immune response in angiogenesis and migration

Journal of Pathology

Volumn 227, Issue 2, 2012, Pages 245-253

  Mohseny, Alexander B ^a   Xiao, Wei ^a   Carvalho, Ralph ^b   Spaink, Herman P ^b   Hogendoorn, Pancras C W ^a   Cleton Jansen, Anne Marie ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

angiogenesis; drug screening; gene expression; immune response; mesenchymal stromal cells; migration; model system; osteosarcoma; transgenic zebrafish

Indexed keywords

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL MIGRATION; E26 ONCOGENE HOMOLOGUE 1; EMBRYO; GENE EXPRESSION; GENETIC ANALYSIS; GENOME; HIGH THROUGHPUT SCREENING; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX CLASS 1 GENE; MATRIX METALLOPROTEINASE 19 GENE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; ONCOGENE; OSTEOSARCOMA; PRIORITY JOURNAL; STEM CELL; SURVIVAL RATE; ZEBRA FISH;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BONE NEOPLASMS; CARBOCYANINES; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; FLUORESCENT DYES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; LUMINESCENT PROTEINS; MATRIX METALLOPROTEINASES, SECRETED; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEIN C-ETS-1; TIME FACTORS; TUMOR ESCAPE; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 84860681385     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.3998     Document Type: Article

References (33)

1. Mohseny AB, Szuhai K, Romeo S, et al., Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 2009; 219: 294-305.
2. Mohseny AB, Hogendoorn PCW,. Concise review: mesenchymal tumors: when stem cells go mad. Stem Cells 2011; 29: 397-403.
3. Tang N, Song WX, Luo J, et al., Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 2008; 466: 2114-2130.
4. Mirabello L, Troisi RJ, Savage SA,. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009; 115: 1531-1543.
5. Bielack SS, Kempf-Bielack B, Delling G, et al., Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-790.
6. Lewis IJ, Nooij MA, Whelan J, et al., Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007; 99: 112-128.
7. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
8. Mohseny AB,. Bone: conventional osteosarcoma. Atlas Genet Cytogenet Oncol Haematol 2008; [Accessed: 22 February 2012]. Available from:.
9. Hauben EI, Weeden S, Pringle J, et al., Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 2002; 38: 1218-1225.
10. Sandberg AA, Bridge JA,. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet 2003; 145: 1-30.
11. Cleton-Jansen AM, Buerger H, Hogendoorn PCW,. Central high-grade osteosarcoma of bone: diagnostic and genetic considerations. Curr Diagn Pathol 2005; 11: 390-399.
12. Tolar J, Nauta AJ, Osborn MJ, et al., Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007; 25: 371-379.
13. Mohseny AB, Tieken C, Van der Velden PA, et al., Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma. Genes Chromosomes Cancer 2010; 49: 1095-1103.
14. Stoletov K, Klemke R,. Catch of the day: zebrafish as a human cancer model. Oncogene 2008; 27: 4509-4520.
15. Deo RC, MacRae CA,. The zebrafish: scalable in vivo modeling for systems biology. Wiley Interdiscip Rev Syst Biol Med 2011; 3: 335-346.
16. Pardo-Martin C, Chang TY, Koo BK, et al., High-throughput in vivo vertebrate screening. Nature Methods 2010; 7: 634-636.
17. Merlino G, Khanna C,. Fishing for the origins of cancer. Genes Dev 2007; 21: 1275-1279.
18. Langenau DM, Keefe MD, Storer NY, et al., Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev 2007; 21: 1382-1395.
19. Feitsma H, Kuiper RV, Korving J, et al., Zebrafish with mutations in mismatch repair genes develop neurofibromas and other tumors. Cancer Res 2008; 68: 5059-5066.
20. Stoletov K, Montel V, Lester RD, et al., High-resolution imaging of the dynamic tumor cell vascular interface in transparent zebrafish. Proc Natl Acad Sci U S A 2007; 104: 17406-17411.
21. Lee LM, Seftor EA, Bonde G, et al., The fate of human malignant melanoma cells transplanted into zebrafish embryos: assessment of migration and cell division in the absence of tumor formation. Dev Dyn 2005; 233: 1560-1570.
22. Marques IJ, Weiss FU, Vlecken DH, et al., Metastatic behaviour of primary human tumours in a zebrafish xenotransplantation model. BMC Cancer 2009; 9: 128.
23. White RM, Sessa A, Burke C, et al., Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell 2008; 2: 183-189.
24. Schroeder A, Mueller O, Stocker S, et al., The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 2006; 7: 3.
25. Nicoli S, Presta M,. The zebrafish/tumor xenograft angiogenesis assay. Nature Protoc 2007; 2: 2918-2923.
26. Nicoli S, Ribatti D, Cotelli F, et al., Mammalian tumor xenografts induce neovascularization in zebrafish embryos. Cancer Res 2007; 67: 2927-2931.
27. Hahne JC, Okuducu AF, Kaminski A, et al., Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth. Oncogene 2005; 24: 5384-5388.
28. Lettau I, Hattermann K, Held-Feindt J, et al., Matrix metalloproteinase-19 is highly expressed in astroglial tumors and promotes invasion of glioma cells. J Neuropathol Exp Neurol 2010; 69: 215-223.
29. Muller M, Beck IM, Gadesmann J, et al., MMP19 is upregulated during melanoma progression and increases invasion of melanoma cells. Mod Pathol 2010; 23: 511-521.
30. Van 't Veer LJ, Dai H, Van de Vijver MJ, et al., Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
31. Buddingh EP, Kuijjer ML, Duim RA, et al., Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage-activating agents. Clin Cancer Res 2011; 17: 2110-2119.
32. Buddingh EP, Schilham MW, Ruslan SE, et al., Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother 2011; 60: 575-586.
33. Mohseny AB, Machado I, Cai Y, et al., Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest 2011; 91: 1195-1205.